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ABSTRACT 22 
Antimicrobial resistance is a global issue currently resulting in fatalities of hundreds of thousands a year 23 
worldwide. Data present in literature illustrate the emergence of many bacterial species that display 24 
resistance to known antibiotics; Acinetobacter spp. is a good example of this. We report here that 25 
Acinetobacter radioresistens has a Baeyer-Villiger monooxygenase (Ar-BVMO) with 100% amino acid 26 
sequence identity to Ethionamide monooxygenase of the MultiDrug-Resistant (MDR) Acinetobacter 27 
baumannii. Both enzymes are phylogenetically only distantly related to other canonical bacterial BVMO 28 
proteins. Ar-BVMO is not only capable of oxidizing two anticancer drugs metabolized by human FMO3, 29 
Danusertib and Tozasertib, but can also oxidize other synthetic drugs such as Imipenem. The latter is a 30 
member of carbapenems, a clinically important antibiotic family used in the treatment of MDR bacterial 31 
infections. Susceptibility tests performed by the Kirby-Bauer disk diffusion method demonstrate that 32 
Imipenem sensitive E. coli BL21 cells overexpressing Ar-BVMO become resistant to this antibiotic. Agar 33 
disc diffusion assay proves that when Imipenem reacts with Ar-BVMO, it loses its antibiotic property. 34 
Moreover, NADPH consumption assay with the purified Ar-BVMO demonstrates that this antibiotic is 35 
indeed a substrate and its product is identified by LC-MS as a BV oxidation product of the carbonyl 36 
moiety of the β-lactam ring. This is the first report of an antibiotic-inactivating BVMO enzyme that 37 
whilst mediating its usual BV oxidation, is also operating by an unprecedented mechanism of carbapenem 38 
resistance. 39 
  40 
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INTRODUCTION 41 
Bacteria classified within the genus Acinetobacter play an increasingly important role in 42 
pathogenesis of human diseases. Among members of this genus, Acinetobacter baumannii is the most 43 
frequently isolated species from humans (found in endotracheal aspirate, blood, peri-anal and wound 44 
secrets) where it is known to manifest multidrug-resistance (MDR) (1). Acinetobacter species are widely 45 
distributed in nature and can be found in soil, water, sewage, and in variety of foodstuffs (1-2). They are 46 
present in the hospital environment especially intensive care units (3-4) as they are inhabitants of healthy 47 
human skin as part of normal flora and can be isolated from dry surfaces and equipment and, they can 48 
easily survive for many days or weeks, even in dry conditions (1-2). Increasing recovery of the MDR A. 49 
baumannii in nosocomial settings is a frightening reality (5,6) and the combination of its environmental 50 
resilience and its wide range of resistance determinants renders it a successful nosocomial pathogen (6). 51 
These MDR strains often spread to cause outbreaks throughout entire cities, countries, and continents (7-52 
10). The importation of MDR strains from areas with high rates of antimicrobial resistance to areas with 53 
historically low rate has been demonstrated. United Kingdom and U.S. military and non-military 54 
personnel returning from operations in Iraq and Afghanistan harboured infections caused by multi-55 
resistant A. baumannii (12-14). Resistance of A. baumannii to the carbapenem Imipenem, which is the 56 
drug of choice for treating serious infections caused by this species, leads to difficult-to-treat nosocomial 57 
infections (7,15-16). Carbapenem resistance results mostly from the expression of acquired carbapenem-58 
hydrolyzing oxacillinases in A. baumannii. The blaOXA-23 gene that confers drug resistance in A. 59 
baumannii, codes for the oxacillinase OXA-23, one of the five Ambler class D β-lactamases (17). 60 
Outbreaks of OXA-23 producing A. baumannii have been reported worldwide and may represent an 61 
emerging threat (18). Poirel and co-workers found that Acinetobacter radioresistens, a commensal 62 
bacterial species that is identified on the skin of hospitalized and healthy patients is the source of the 63 
blaOXA-23 gene (19).  64 
Recently we have identified a novel Baeyer-Villiger monooxygenase (Ar-BVMO) in A. 65 
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radioresistens strain S13 (20). Baeyer-Villiger monooxygenases (BVMOs) are flavin-containing enzymes 66 
that mediate specific Baeyer-Villiger oxidations on the carbonyl moiety of substrates. Ketones are 67 
converted into the corresponding esters and lactones by the Baeyer-Villiger reaction. BVMO enzymes are 68 
abundant in bacterial, fungal and plant genomes but they are absent in animal and human genomes. All 69 
characterized BVMOs contain a flavin cofactor that is crucial for catalysis while NADH or NADPH is 70 
required as electron donor. Most reported BVMOs are soluble proteins in contrast to many other 71 
monooxygenase systems that are often found to be membrane bound. BVMOs are divided into three 72 
different types according to their general characteristics (21). Type I enzymes contain a tightly bound 73 
FAD cofactor, are NADPH-dependent, possess two Rossmann folds for dinucleotide binding and a 74 
conserved Baeyer-Villiger motif, a fingerprint sequence (FXGXXXHXXXW(P/D))  involved in catalysis 75 
(22). Type II enzymes do not present the Baeyer-Villiger sequence motif, utilize FMN as coenzyme and 76 
NADH as co-substrate whereas type 0 use FAD and NAD(P)H and lack the BVMO fingerprint motif 77 
(23). A heme-containing BVMO has also been reported belonging to the cytochrome P450 superfamily 78 
(24). Earlier studies had already suggested Baeyer-Villiger activity of other eukaryotic cytochrome P450 79 
enzymes (25). This finding indicates that during evolution several different enzymes have evolved into 80 
Baeyer-Villiger monooxygenases. Most biochemical and biocatalytic studies have been performed with 81 
Type I BVMOs (23). This is partly due to the fact that they represent relatively uncomplicated 82 
monooxygenase systems. These monooxygenases are typically soluble and composed of only one 83 
component. Expression systems have been developed for a number of Type I BVMOs, while no 84 
recombinant expression has been reported for Type II. All these enzymes are known to perform various 85 
catalytic activities on different compounds even partially sharing their substrate profile. BVMOs are also 86 
known to perform oxygenation on heteroatom-containing compounds. The first evidence of soft 87 
nucleophilic containing substrate oxidation was reported with CHMO from Acinetobacter sp. that showed 88 
4-tolyl ethyl sulfide conversion to the corresponding (S)-sulfoxide with a modest enantioselectivity (26). 89 
BVMOs may also have medical relevance as in the case of Ethionamide monooxygenase (EtaA), a Type I 90 
BVMO capable of converting a range of ketones into the corresponding esters (27). Except for catalyzing 91 
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Baeyer-Villiger oxidations, the enzyme is also able to oxidize the sulfide moieties of several 92 
antitubercular thioamide drugs (27-28). The oxidized drugs appear to be highly toxic to the mycobacteria, 93 
indicating that Ethionamide monooxygenase acts as a prodrug activator.  94 
Phylogenetic analysis placed the sequence of Ar-BVMO together with Mycobacterium tuberculosis EtaA 95 
(20) with only a distant relation to the other known class I BVMO proteins. In vitro experiments carried 96 
out with the purified enzyme confirmed that this novel BVMO is indeed capable of typical Baeyer-97 
Villiger reactions as well as oxidation of the prodrug Ethionamide (20). Ortiz de Monellano’s group (28) 98 
demonstrated that Ethionamide is also oxidized by human flavin-containing monooxygenase 3 (FMO3). 99 
Human FMO enzymes are a superfamily of flavoprotein monooxygenases involved in the detoxification 100 
of a wide range of xenobiotics containing a soft nucleophile, usually nitrogen or sulfur (29). Since Ar-101 
BVMO has been shown to oxidize Ethionamide, we wondered whether this enzyme could play a role in 102 
detoxification of xenobiotics, recognizing synthetic compounds such as drugs, typically recognized by 103 
human FMO3. We took into consideration two synthetic drugs, Danusertib and Tozasertib, shown to be 104 
N-oxygenated by human FMO3 (30-31) and certainly not present in the natural environment of this 105 
bacterium. Species belonging to Acinetobacter genus have been reported as one of the major super-bugs, 106 
resistant to antibiotic treatment (32). The presence in their genomes of genes coding for monooxygenases 107 
similar to those involved in drug metabolism in humans becomes highly relevant when tackling the threat 108 
they pose.  109 
We report here that the overexpression of Ar-BVMO in E. coli renders it resistant to Imipenem and show 110 
that this enzyme whilst mediating its usual Baeyer-Villiger oxidation on the carbonyl moiety of the β-111 
lactam ring, is also operating by an unprecedented mechanism of carbapenem resistance. In future, if 112 
under physiological conditions appreciable carbapenemase activity is attributed to this monooxygenase, it 113 
could represent a new target for drug design in the battle against carbapenems’ resistance in 114 
Acinetobacter. 115 
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MATERIALS and METHODS 116 
Bacterial strains 117 
Escherichia coli strain BL21 (DE3) (Invitrogen) transformed with the expression vector plasmid pT7 118 
harbouring the gene coding for Acinetobacter radioresistens S13 Baeyer-Villiger monooxygenase (Ar-119 
BVMO) (20) and not transformed BL21 cells. 120 
 
Reagents 121 
FAD, acetonitrile, NADPH, Imipenem, methanol and salts were purchased from Sigma-Aldrich (Milan, 122 
Italy). Tozasertib and Danusertib were purchased from Aurogene (Rome, Italy). 123 
Sequence retrieval, alignment and phylogenetic analysis 124 
Amino acid sequences from completely sequenced genomes of proteobacteria were retrieved from 125 
GenBank database (http://www.ncbi.nlm.nih.gov). BLAST (33) probing of database was performed with 126 
the BLASTP option of this program using default parameters. The ClustalW program (34) was used to 127 
perform pairwise and multiple amino acid sequence alignments.  128 
Preliminary multiple alignments of amino acid sequences were generated with the program ClustalW 129 
using default gap penalties. The selection of characters eligible for the construction of phylogenetic tree 130 
was optimized by comparing entire sections of all the available BVMO alignments with comprehensive 131 
inventories of significant binary alignments obtained by BLAST probing of the protein database with 132 
representative bacterial sequences. The structure and organization of the BVMOs were deduced from the 133 
data present in GenBank from the microorganisms available in data banks. BLAST probing of the protein 134 
databases was performed with the BLASTP program choosing sequences with an E-value of 0.0, 100% 135 
query coverage and a threshold of 99% sequence identity. For construction of the phylogenetic tree, a 136 
representative of each class of BVMO was selected to demonstrate its relationship to the Ar-BVMO. 137 
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The phylogenetic tree was constructed using the Distance Matrix (DM) method using MEGA version 4 138 
(35), after multiple sequence alignment and truncation to the same length. Distances according to the 139 
Kimura two-parameter model (36) and clustering with the neighbor-joining method  (37) were determined 140 
using bootstrap values based on 1,000 replications. 141 
Expression and purification of recombinant Ar-BVMO  142 
The expression and purification of Ar-BVMO were performed as previously reported (20). After Ni-NTA 143 
affinity chromatography, the heterologous expression of Ar-BVMO yielded 8 mg of purified protein per 144 
litre of culture. The concentration of the pure Ar-BVMO was determined by spectroscopy with the peak 145 
absorbance at 450 nm and the extinction coefficient of free FAD  =11,300 M-1 cm-1).  146 
Ar-BVMO incubation with Tozasertib, and Danusertib  147 
N-oxygenation of the anticancer drugs Danusertib and Tozasertib was evaluated by incubating a mixture 148 
of 0.3 µM of purified enzyme in 50 mM potassium phosphate buffer (pH 7.4), 0.5 mM NADPH and 149 
increasing amounts of substrates (6, 12.5, 25, 50, 75, 100, 150, 200, 300 and 400 µM) in a final volume of 150 
200 µl. Incubations were carried out at 37°C for 15 min and were terminated by the addition of 100 µl of 151 
ice-cold methanol. The aqueous supernatant was centrifuged at 2,000x g for 10 min and was subjected to 152 
High Pressure Liquid Chromatography. Kinetic parameters related to the turnover were determined 153 
through Michaelis-Menten kinetics using SigmaPlot Software. 154 
Analysis by High Pressure Liquid Chromatography (HPLC) 155 
HPLC was performed on an Agilent quaternary pump HPLC system (Agilent Technologies) equipped 156 
with an analytical C18 column (4.6 x150 mm, 5 m). The method to separate Tozasertib and Tozasertib 157 
N-oxide” and Danusertib from Danusertib N-oxide” used a mobile phase of 78% methanol and 22% 158 
distilled water at a flow rate of 1.0 ml/min. The formation of Tozasertib N-oxide was monitored at the 159 
wavelength of 250 nm while the Danusertib N-oxide product was monitored at 295 nm (30-31). The 160 
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kinetic analysis of N- or S-oxygenation was carried out using a nonlinear regression analysis program 161 
(SigmaPlot). 162 
Susceptibility testing 163 
Imipenem sensitivity of E. coli BL21 cells (i) transformed with pT7-Ar-BVMO induced with IPTG, (ii) 164 
not induced and, (iii) negative control- transformed with pT7 (carrying another gene (38)) induced with 165 
IPTG, was performed by disc diffusion method (39) according to the latest updated guidelines (2014) of 166 
the European Committee of Antimicrobial Susceptibility Testing (EUCAST) (www.eucast.org) using 167 
standard antibiotic disks (Oxoid) and Mueller-Hinton agar (MHA) plates (Sigma). There were five 168 
replicates for each condition tested. Inhibition zones measured as mean diameter were categorized as 169 
‘susceptible’ (S), ‘intermediary’ (I) and ‘resistant’ (R) according to EUCAST standards. 170 
The effect of Ar-BVMO activity on the antimicrobial properties of Imipenem was subsequently assessed 171 
by a microbiological assay. Inactivation reaction contained 3 mM Imipenem, 2 mM NADPH and 100 µM 172 
of purified Ar-BVMO in 50 mM phosphate buffer pH 7.4, in a total volume of 0.5 ml. The reaction was 173 
allowed to proceed for 30 min at 37°C. A control reaction was performed in the same conditions 174 
described above without adding NADPH. Fifty µl aliquots of the two reactions were used for agar 175 
diffusion plate tests (40) in order to evaluate the effect of metabolized Imipenem on the growth of 176 
sensitive E. coli BL21 cells. MH agar plates were prepared using sterile MHA. Upon solidification of the 177 
agar medium, sensitive not transformed BL21 and transformed not induced BL21 cells were spread over 178 
the plate surface at a concentration of 0.5 MacFarland. Then, a well was made in the centre of each plate 179 
using a sterile Pasteur pipette. After adding 50 µl of the Ar-BVMO-Imipenem reaction with and without 180 
NADPH, an uninoculated agar plug larger than the well was placed over it to prevent volatilization of the 181 
enzymatic reaction into the headspace of the Petri dish (40). The diameter of the growth inhibition zone 182 
was measured after 24 hours from the application of the test substance at 37°C. There were five replicates 183 
for each condition tested. 184 
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Enzymatic activity assay 185 
Enzyme activity was measured spectrophotometrically by monitoring the substrate-dependent decrease in 186 
NADPH concentration at 340 nm (340 nm = 6.22 mM-1 cm-1). Reaction mixtures contained 50 mM Tris-187 
HCl pH 8.0, 200 µM NADPH, and a range from 5 to 150 µM of Imipenem using air-saturated buffers. 188 
Steady state kinetic parameters were determined by fitting the initial rates, calculated from the first 200 s 189 
of the reaction, to the standard Michaelis-Menten equation using SigmaPlot program. Experiments were 190 
conducted in triplicates. 191 
LC-MS/MS analysis 192 
The chromatographic separations were run on a Phenomenex Luna C18 column, 150 × 2.0 mm, 3 μm 193 
particle size (Phenomenex, Torrance, CA, USA). Injection volume was 10 μL and flow rate 0.2 mL min-1. 194 
Isocratic mobile phase composition was adopted: 5:95 acetonitrile/aqueous formic acid 0.05%. A LTQ -195 
Orbitrap hybrid mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with an atmospheric 196 
pressure interface and an ESI ion source was used. The LC column effluent was delivered into the ion 197 
source using nitrogen as sheath and auxiliary gas. The needle voltage was set at the 4.5 kV value. The 198 
heated capillary value was maintained at 270°C. The acquisition method used was previously optimized 199 
in the tuning sections for the analyte ion (capillary, magnetic lenses and collimating octapoles voltages) in 200 
order to achieve the maximum of sensitivity. Spectra were acquired in the positive HRMS and MS/MS 201 
mode, precursor ions 300 and 316, normalized collision energy 25 %, mass range 320-80 m/z. 202 
RESULTS 203 
Phylogenetic tree of the Ar-BVMO was inferred from the selected sequences by DM method as 204 
mentioned in Materials and Methods section. As shown in Figure 1, the clade comprising Mycobacterium 205 
tuberculosis EtaA, Ar-BVMO and A. baumannii EtaA belong to a separate group, distant from the other 206 
BVMO proteins. Furthermore, Ar-BVMO shares 100% amino acid sequence identity with the 207 
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Ethionamide monooxygenase of MDR A. baumannii strains (GenBank ID: gb|EXB35767.1|, 208 
gb|EXB73644.1|, gb|EXE14728.1| and gb|KCX39290.1|).  209 
Previously in our laboratory we had tested different therapeutic drugs as possible substrates of this human 210 
hepatic enzyme including Danusertib and Tozasertib (29-30). Tozasertib (VX-680) and Danusertib (PHA-211 
739358) are inhibitors of Aurora kinases which have been identified as a potential target in anticancer 212 
therapy. As a starting point, the possibility of these two inhibitors acting as substrates for Ar-BVMO 213 
enzyme was tested by investigating whether any enzymatic products could be detected. After each set of 214 
reactions at 37 ºC in the presence of NADPH, the product(s) was separated by HPLC and the data 215 
obtained are shown in Figure 2. As can be seen from in the figure, the expected N-oxides were detected 216 
with shorter retention times of 3.7 min for Danusertib N-oxide” (Figure 2A) and 4.1 min for Tozasertib 217 
N-oxide” (Figure 2C), in agreement with the previously published data by our group (30-31). The 218 
catalytic activity of Ar-BVMO towards two kinase inhibitors, Danusertib and Tozasertib, was 219 
investigated. Enzymatic reactions were carried out with the purified recombinant Ar-BVMO in the 220 
presence of NADPH and increasing amounts of each drug as reported in the experimental section. Kinetic 221 
parameters for the N-oxygenation for Danusertib (Figure 2B) and Tozasertib (Figure 2D) were determined 222 
by nonlinear regression analysis with a calculated KM value of 352 ± 58 µM and 54.3 ± 8.3 µM, 223 
respectively. The corresponding Vmax values of  8.1 and 7.4 nmol/min/mg of protein were also calculated 224 
for Danusertib and Tozasertib, respectively. These results confirm that the bacterial enzyme is indeed able 225 
to metabolize these two synthetic drugs. 226 
Acquisition of Imipenem resistance by Escherichia coli overexpressing Ar-BVMO- Once it was 227 
proven that the bacterial Ar-BVMO is capable of metabolizing the synthetic drugs tested, our attention 228 
was turned to antibiotics as another class of synthetic drugs and directly relevant to the MDR effects seen 229 
in Acinetobacter spp. Initially, in order to understand whether the expression of Ar-BVMO in Imipenem 230 
sensitive E. coli BL21 cells could confer resistance to Imipenem (i.e. enzymatic reaction of Ar-BVMO 231 
with Imipenem resulting in a product no longer active as an antibiotic), a disc diffusion assay was 232 
performed following EUCAST guidelines (www.eucast.org). According to EUCAST clinical breakpoint 233 
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table v. 5.0 (valid from 2015/01/01) for Enterobacteriaceae, the zone diameter breakpoint for Imipenem 234 
is ≥22 mm for sensitivity and <16 mm for resistance, corresponding to MIC values of 2 and 8 mg/L of 235 
Imipenem, respectively, for sensitive and resistant Enterobacteriaceae including E. coli, which is the most 236 
important model organism of this family. As shown in Figure 3, the average diameter of the inhibition 237 
zone for E. coli BL21 cells (Figure 3 top panel-A), the same E. coli strain transformed with pT7-Ar-238 
BVMO but not induced (Figure 3 top panel-B) and E. coli strain transformed with pT7 (negative control) 239 
IPTG-induced (Figure 3 top panel-C) was measured as 25.5 mm, 24.0 mm, and 28.0 mm, respectively. 240 
The results clearly show that the E. coli BL21 cells are sensitive to Imipenem (zone diameter breakpoint 241 
≥22 mm) but there is no visible inhibition zone when E. coli BL21 cells are transformed and the 242 
expression of Ar-BVMO is induced by IPTG i.e. the cells became resistant to Imipenem (zone diameter 243 
breakpoint <16 mm), Figure 3 top panel-D. These data provided the preliminary but encouraging 244 
evidence that the over expression of Ar-BVMO in Imipenem sensitive cells may result in antibiotic 245 
resistance. 246 
Ar-BVMO catalyses the inactivation of Imipenem- The effect of Ar-BVMO activity on the 247 
antimicrobial properties of Imipenem was further studied by a microbiological assay (41). The reaction 248 
product(s) of purified Ar-BVMO and Imipenem was loaded in a well in the MH agar plates where 249 
Imipenem sensitive BL21 cells and BL21 carrying pT7-Ar-BVMO whose gene expression was not 250 
induced, were grown at 37°C for 24 h. As shown in Figure 3 bottom panel-B and D Imipenem is not 251 
active after the reaction with Ar-BVMO since both not transformed and transformed but not induced 252 
BL21 exhibited an inhibition zone of 12.0 mm and 0.5 mm, respectively. When the enzymatic reaction 253 
without NADPH (negative control) was deposited in the agar well the diameter of the inhibition zone 254 
were 24.0 mm (Figure 3 bottom panel-A) and 24.5 mm (Figure 3 bottom panel-C) for not transformed 255 
BL21 and transformed but not induced BL21, respectively. These data also support the idea that the 256 
enzymatic reaction of Ar-BVMO converts Imipenem into an inactive compound no longer possessing its 257 
original antibacterial property. 258 
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Catalytic activity of purified Ar-BVMO in presence of Imipenem and identification of the 259 
products- Subsequent to the in vivo data, a spectroscopic method was used to measure the activity of the 260 
purified Ar-BVMO in the presence of Imipenem. In order to determine the steady state kinetic parameters 261 
for Ar-BVMO turnover, the NADPH consumption assay which has previously been described in literature 262 
as an efficient system to evaluate KM (42), was used. This method relies on the spectrophotometric 263 
monitoring of the consumption of the co-substrate NADPH at 340 nm, in the presence of increasing 264 
concentrations of Imipenem. The experimental data from the NADPH consumption were fitted to a 265 
Michaelis-Menten curve used for the determination of a KM value of 12.3 ± 0.8 µM (Figure 4) and a Vmax 266 
value of  468.2 ± 9.6 nmol/min/mg of protein. These values are in the same range as those reported for 267 
known substrates of other BVMO enzymes (42) indicating that Imipenem could be a real substrate of Ar-268 
BVMO.  269 
In order to identify the product(s) of the Ar-BVMO reaction with Imipenem, LC-MS experiments were 270 
carried out. Imipenem incubation (100 µM) was performed in phosphate buffer (50 mM, pH 7.4) at room 271 
temperature and monitored by LC-high resolution mass spectrometry at different reaction times. Ar-272 
BVMO and NADPH concentrations were 0.45 and 200 µM, respectively. The incubation mixture was 273 
simply ten-fold diluted using elution mobile phase and injected in the LC-MS instrument. Imipenem peak 274 
was eluted at 4.7 min. The main metabolite was detected as a double peak (5.0 and 5.5 min) due to a 275 
mixture of isobaric products. The accuracy of orbitrap high resolution mass determination allows to 276 
deduce that the elemental composition of the two compounds correspond to C12H18N3O5S with 1.05 ppm 277 
of error (MH+ ion at 316.0962 m/z). A classical Baeyer-Villiger asymmetric oxygen insertion can explain 278 
this finding as shown in Figure 5.  279 
 An analogous BV catalytical synthetic reaction was described regarding a similar lactam 280 
(bicyclo[3.2.0]hept-3-en-1-one) (43).  In order to elucidate the structure, a MS/MS study was performed. 281 
High resolution MS/MS spectra of Imipenem and the corresponding Ar-BVMO oxidized products are 282 
shown in figures 6a and 6b, respectively. The  MSn study of Imipenem precursor ion (300.0867 m/z) 283 
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allows to hypothesize the fragmentation pathway shown in Figure 7. The main fragmentation pathways 284 
are the (consecutive) losses of water and carbon dioxide. The elimination of the amidino-ethylthio- lateral 285 
chain is noteworthy. High resolution mass defect data were fundamental to differentiate CO2 and NH-CH-286 
NH2 losses, both with nominal mass of 44 Da but with different significant digits. The interpretation of 287 
MS/MS spectrum of Ar-BVMO metabolites is reported in Figure 8. A double CO2 loss characterizes the 288 
spectrum. The intense ion due to the loss of the amidino-ethyilthio lateral chain confirms that oxygen 289 
insertion occurred on the lactamic ring. A possible intramolecular hydrogen bond justifies both the 290 
proposed formation of a new lactone cyclic structure and the chromatographic behavior of the two 291 
metabolites which are more retained than the parent compound on the reverse phase column. Successive 292 
losses of water, ammonia and ethylamidine molecules could explain all the obtained fragment ions. The 293 
same fragmentation pathway is valid in the interpretation of MS/MS spectrum of the ion corresponding to 294 
the asymmetrical isomer reported in Figure 5. 295 
DISCUSSION 296 
The World Health Organization (WHO) has recently classified antibiotic resistance as one of the three 297 
greatest threats to human health. Theβlactams are one of the most important and frequently used 298 
classes of antibiotics in medicine and are essential in the treatment of serious gram-negative infections. 299 
The past two decades have seen substantial increases in the utilization of carbapenems such as Imipenem 300 
and Meropenem. Predictably, this increase in carbapenem consumption has been accompanied by the 301 
emergence of carbapenem-resistant gram-negative pathogens (44). The initial and seemingly unstoppable 302 
success of antibiotics has been countered by an escalation of resistance mechanisms in bacteria with the 303 
emergence of many genera of bacteria that are resistant to all antibiotics (45-47). The genus Acinetobacter 304 
epitomizes this trend and deserves close attention. Acinetobacter spp. display mechanisms of resistance to 305 
all existing antibiotic classes as well as a prodigious capacity to acquire new determinants of resistance 306 
(3, 48-49).  307 
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Furthermore, Acinetobacter spp. appears to be well suited for genetic exchange and is among a unique 308 
class of gram-negative bacteria that are described as naturally transformable” (50). The increasing 309 
recovery in the clinic of multidrug-resistant A. baumannii is a frightening reality (6).  A previously 310 
published study describing the genome sequences of both susceptible (SDF) and resistant (AYE) isolates 311 
of A. baumannii has shed light on the abundance of resistance genes found in this organism (51). Fournier 312 
and co-workers identified a resistance island in AYE that contained a cluster of 45 resistance genes in the 313 
MDR isolate. Among the key resistance genes identified were those coding for β-lactamases, various 314 
aminoglycoside-modifying enzymes, and tetracycline efflux pumps. A significant fraction of the open 315 
reading frames were located in putative alien islands, indicating that the genome acquired a large amount 316 
of foreign DNA. More than 30 years ago it was demonstrated that Acinetobacter spp. could acquire 317 
antimicrobial resistance factors through conjugation of plasmids (52). The genome of A. baumannii not 318 
only contains a gene coding for an Ethionamide monooxygenase that phylogenetically is part of the same 319 
group as that of Ar-BVMO but also shares a 100% amino acid sequence identity with Ar-BVMO. As 320 
mentioned earlier, human FMO3, Ar-BVMO and M. tuberculosis EtaA can metabolize a common 321 
substrate, ethioamide. Based on this, we investigated the ability of Ar-BVMO to use as substrate two 322 
potent and selective Aurora kinase inhibitors, Danusertib and Tozasertib, used for the treatment of solid 323 
tumors and hematopoietic cancers and metabolized by human FMO3 in liver microsomes (53-54). 324 
In vitro experiments with recombinant Ar-BVMO demonstrated that both Danusertib and Tozasertib are 325 
monooxygenated by Ar-BVMO with KM values comparable to those obtained with recombinant human 326 
FMO3 (30). The reason why a prokaryotic flavin monooxygenase should metabolize substrates that are 327 
typically metabolized by the eukaryotic FMO enzymes is not clear. Since both proteins, together with 328 
EtaA belong to the same class of flavoproteins and are involved in detoxification processes, it can be 329 
speculated that during evolution some FMO proteins became BVMOs providing the acquiring organism 330 
new metabolic capabilities. This is not the first example of a bacterial FMO that shares the same substrate 331 
with a human flavoprotein. Chen and co-workers (55) showed that a FMO from Methylocella silvestris is 332 
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able to oxidize trimethylamine that is a typical substrate of eukaryotic FMO enzymes. It can be assumed 333 
that the A. baumanni enzyme would be able to monooxygenate the two anticancer drugs even if further 334 
experiments are required to confirm this. It could be hypothesized that genetic exchange between the 335 
progenitor (A. radioresistens) and its recipient of clinical relevance (A. baumannii), may have occurred in 336 
humans (19) leading to the BVMO acquisition by the latter species. Both A. radioresistens and A. 337 
baumannii are identified on the human skin, especially in hospitalized patients, it is therefore possible that 338 
BVMO gene exchange may have occurred at this location (4). In order to provide support for the 339 
hypothesis of lateral gene transfer, the genetic context of the Ar-BVMO (Accession number GG705134.1) 340 
was evaluated and compared to that of EtaA of Acinetobacter baumannii strains 1461402 (Accession 341 
number JEWP01000001) 230853 (Accession number JEWP01000002), 983759 (Accession number, 342 
JEX001000002); 263903-1 (Accession numberJMNM01000001). The genes flanking upstream and 343 
downstream of the Ar-BVMO were found to be not only identical but also in the same position as those of 344 
the four A. baumannii strains. In addition, the GC content (56) of the ethionamide monooxygenase genes 345 
of the four A. baumannii strains was compared with A. radioresistens genome content. The GC% was 346 
calculated using the Endmemo software (www.endmemo.com/bio/gc.php) and the values were 42.65% 347 
and 42.69% for A. baumannii Etha gene and Ar-BVMO of A. radioresistens, respectively. These data are 348 
not in support of a horizontal gene transfer unless a large portion of the genome has been transferred from 349 
A. radioresistens to A. baumannii and therefore a more in depth analysis is required which is outside the 350 
scope of this work. 351 
The presence of a flavin monooxygenase in a MDR bacterium that has 100% sequence identity with Ar-352 
BVMO (i.e. identical protein) with pro-drugs as substrates strongly suggests that the EtaA could be used 353 
by A. baumannii to metabolize/detoxify different types of synthetic drugs including antibiotics in exactly 354 
the same way as Ar-BVMO.  355 
In this work we have demonstrated that sensitive E. coli cells overexpressing Ar-BVMO became resistant 356 
to the antibiotic Imipenem. NADPH consumption assay shows that Imipenem is a substrate of Ar-BVMO 357 
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and agar well diffusion assay proves that the enzyme destroys the antibacterial property of the antibiotic. 358 
Like all other βlactams, Imipenem inhibits bacterial cell wall synthesis by binding to and inactivating 359 
penicillin binding proteins. Antibiotic resistance can occur via three general mechanisms: prevention of 360 
interaction of the drugs with target, efflux of the antibiotic from the cell, and direct destruction or 361 
modification of the compound. The most prevalent resistance mechanism against β-lactams is the 362 
production of βlactamases. Among the βlactamases, metalloenzymes are distinguished by having a 363 
zinc ion required for enzymatic activity (57). Sometimes referred to as carbapenemases, they are able to 364 
hydrolyze many β-lactam antibiotics including carbapenems (58).  In the present work, for the first time, 365 
we demonstrate that a bacterial flavin monooxygenase is able to metabolize Imipenem in a way that it is 366 
no longer active by modification of the parent compound. Two molecules with evidence of the 367 
transformation of the lactam ring, according to Baeyer-Villiger oxygen insertion mechanism, were 368 
identified by LC-HRMS analysis. This is not the first report of a flavin monooxygenase catalysing 369 
antibiotic inactivation since Yang and co-workers have previously reported TetX, a flavin-dependent 370 
monooxygenase from bacteria of the genus Bacteroides, that regioselectively hydroxylates the 371 
tetracycline substrate (41). However, they could not capture the product and suggested that the resulting 372 
hydroxylated product was an unstable compound that underwent a non-enzymatic decomposition (41).  373 
Future efforts will be focused on the screening of other carbapenem members and, if under physiological 374 
conditions appreciable carbapenemase activity is attributed to this monooxygenase enzyme, it could 375 
represent a new target for drug design in the battle against carbapenems’ resistance in Acinetobacter. 376 
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FIGURE 1. Phylogenetic position of Ar-BVMO in relation to the other BVMOs and Acinetobacter baumannii Ethionamide 
monooxygenase. Neighbor-joining consensus tree. 
STMO Rhodococcus rhodochrous= steroid monooxygenase (BAA24454.1); STMO Mycobacterium avium= steroid monooxygenase 
(BAN31365.1); CHMO Hyphomonas neptunium= steroid monooxygenase (YP_760152.1); PAMO Thermobifida fusca= phenylacetone 
monooxygenase (Q47PU3.1); CHMO Acinetobacter sp. SE19= cyclohexanone monooxygenase (AF282240_5); CPMO Pyrenophora 
treitici-repentis= cyclopentanone monooxygenase (XP_001942142.1); CPMO Paracoccidioides sp. lutzi= cyclopentanone 
monooxygenase (XP_002792362.1); CPMO Rhodococcus josti= cyclopentanone monooxygenase (YP_703208.1); CPMO Comamonas sp. 
NCIMB 9872= cyclopentanone monooxygenase (BAC22652.1); CDMO Rhodococcus ruber= cyclododecanone monooxygenase 
(AAL14233.1); CDMO; Hyphomonas neptunium ATCC33707= cyclododecanone monooxygenase (ABI76430.1);  CPDMO Pseudomonas 
sp. HI-70= cyclopentadecanone monooxygenase (BAE93346.1); HAPMO Gordonia bronchialis= hydroxyacetophenone monooxygenase  
(ACY20506.1); HAPMO Mycobacterium kansasii= hydroxyacetophenone monooxygenase (ZP_04749205.1); HAPMO Pseudomonas 
putida= hydroxyacetophenone monooxygenase (ACJ37423.1); HAPMO Phenylobacterium zucineum= hydroxyacetophenone 
monooxygenase (YP_002130647.1); HAPMO Burkholderia sp. CCGE1002= hydroxyacetophenone monooxygenase (ADG19710.1); EtaA 
Mycobacterium tuberculosis H37Ra= Ethionamide monooxygenase (YP_001285245.1); EtaA Mycobacterium tuberculosis KZN1435= 
Ethionamide monooxygenase (YP_003033907); EtaA Mycobacterium tuberculosis SUMu001= Ethionamide monooxygenase 
(ZP_07416557.1); EtaA Mycobacterium tuberculosis H37Rv= Ethionamide monooxygenase (NP_218371.1); EtaA Mycobacterium 
complex= Ethionamide monooxygenase (WP_003910007.1); BVMO Acinetobacter radioresistens SK82= Baeyer-Villiger monooxygenase 
(EET82318.1); BVMO Acinetobacter radioresistens SH164= Baeyer-Villiger monooxygenase (EEY85682.1); BVMO Acinetobacter 
radioresistens NIPH 2130= Baeyer-Villiger monooxygenase (ENV85773.1); EtaA Acinetobacter baumannii 1461402= Ethionamide 
monooxygenase (EXB35767.1); EtaA Acinetobacter baumannii 230853= Ethionamide monooxygenase (EXB73644.1); EtaA Acinetobacter 
baumannii 983759= Ethionamide monooxygenase (EXE14728.1); BVMO Acinetobacter radioresistens WC-A-157= Baeyer-Villiger 
monooxygenase (EJQ34398.1); BVMO Acinetobacter radioresistens= Baeyer-Villiger monooxygenase (ADF32068.2); BVMO 
Acinetobacter radioresistens S13= Baeyer-Villiger monooxygenase (GU145276.2); EtaA Acinetobacter baumannii 263903-1= 
Ethionamide monooxygenase (KCX39290.1). 
  
A B 
FIGURE  4 
C D 
  
  
FIGURE 2. Danusertib and Tozasertib oxidation by purified recombinant Ar-BVMO. HPLC traces for Danusertib (A) and Tozasertib 
(C) conversion. The red trace shows Ar-BVMO reaction, the black trace shows the negative control without enzyme, the green 
trace shows the positive control with purified recombinant human FMO3. The retention times are 6.4 min for Danusertib and 3.9 
min for the product “Danusertib N-oxide” and 6.5 min for Tozasertib and 4.4 min for the product “Tozasertib N-oxide”. Michaelis 
Menten curve of the enzymatic “Danusertib N-oxide” (B) and “Tozasertib N-oxide” (D) product formed in the presence of 
increasing amount of Danusertib and Tozasertib, respectively. 
 

FIGURE 3. Imipenem antibiograms of E. coli BL21 cells against disk embedded Imipenem (Top panel). E. coli BL21 cells were plated 
on Muller Hinton agar plate at a concentration of 0.5 MacFarland and incubated overnight at 37°C.  A) E. coli BL21; B) E. coli BL21 
transformed with Ar-BVMO-pT7 but not induced; C) E. coli BL21 transformed with pT7 plasmid and induced with IPTG (negative 
control); D) E. coli BL21 transformed with pT7-Ar-BVMO and induced with IPTG.  
Agar well diffusion assay (Bottom panel). Imipenem sensitive not transformed (A, B) and transformed but not induced BL21 cells 
(C, D) were spread over the plate surface of MHA at a concentration of 0.5 MacFarland. Fifty ml of the reaction product/s between 
Ar-BVMO and Imipenem were placed inside a well in the center of each plate. B, D:  reaction with NADPH; A, C:  reaction without 
NADPH. 
 

FIGURE 4. NADPH consumption assay for Ar-BVMO in the presence of Imipenem. Plot of enzymatic reaction velocity versus 
Imipenem concentration fitted to the Michaelis-Menten equation (R2 = 0.998). Data are shown as mean ± SD of three different 
measurements. 
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FIGURE 5. Asymmetric oxygen insertion in the carbapenem ring of imipenem according to the classical Baeyer-Villiger mechanism.   

FIGURE 6. MS/MS high-resolution spectra of Imipenem and its metabolite. Spectrum of Imipenem 300.0987 m/z precursor ion (A) 
and spectrum of the first eluted M+O metabolite 316.0965 m/z  (B) precursor ion acquired at 25% collision energy, in the range 
80-320 m/z. 
 
NO
OH
COOH
S
NH
H2N
C12H18N3O4S
300.0987 m/z
NH2
HN-
- H2O
N
O
COOH
S
NH
H2N
C12H16N3O3S
282.0914 m/z
- CO2
N
O
S
NH
H2N
C11H16N3OS
238.0986 m/z
- CO2
N
O
OH
S
NH
H2N
C11H18N3O2S
256.1092 m/z
- C3H6
N
O S
NH
H2N
C8H10N3OS
196.0519 m/z
- CHNO
S
NH
H2N
C7H9N2S
153.0462 m/z
N
O
OH
S
C10H14NO2S
212.0771 m/z
- C5H7NO3
-CO2, H2O
N
O
S
NH
H2N
C11H16N3OS
238.0986 m/z
- C2H4O - C2H5N
N
O
S
H2N
C9H11N2OS
195.0593 m/z (base peak)
N
S
NH
H2N
C9H12N3S
194.0728 m/z
- HCN (168.0459 m/z)
- HCONH2 (150.0354 m/z)- C2H4 (166.0414 m/z)
- NH3 (177.0461 m/z)
S
NH
H2N
C3H7N2S
103.0320 m/z
- C9H11NO4
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